Siemens Healthineers and Mayo Clinic have expanded their strategic collaboration to advance the diagnosis and treatment of neurodegenerative diseases and cancer. Through this renewed agreement, the partners will accelerate the development and clinical adoption of next-generation imaging and interventional technologies.
In addition to ongoing work in neurodegenerative disorders, the expanded partnership now includes focused efforts in prostate cancer and metastatic liver tumors.
Advancing Precision Through Imaging and AI
Eric Williamson, Chair of Diagnostic Radiology at Mayo Clinic, stated that the collaboration aims to integrate advanced imaging systems, artificial intelligence (AI), and innovative treatment approaches into routine clinical care. By doing so, the teams intend to enable earlier diagnosis and deliver more personalised treatment plans.
He emphasised that the ultimate goal is to make care more precise, less invasive, and more responsive to individual patient needs.
Enhancing Neurodegenerative Disease Diagnosis
In the field of neurodegenerative diseases, the collaboration will prioritise AI-enabled magnetic resonance imaging (MRI) protocols to improve diagnostic accuracy and patient monitoring.
Furthermore, the teams will focus on accelerating the clinical adoption of ultra-high-field MRI technologies. These systems provide higher resolution and enhanced contrast, thereby supporting more accurate diagnostic assessments and improved surgical planning in complex neurological conditions.
For example, in Alzheimer’s disease, MRI scans often reveal characteristic patterns of brain shrinkage. By refining imaging capabilities, clinicians may detect subtle changes earlier and monitor disease progression more effectively.
Transforming Prostate and Liver Cancer Management
In prostate cancer care, researchers will evaluate how AI can help minimise unnecessary biopsies. At the same time, they will work to integrate advanced imaging tools directly into diagnostic and therapeutic procedures, thereby improving precision and reducing patient burden.
In liver cancer, particularly metastatic disease, the collaboration will concentrate on translating image-guided technologies into clinical practice. These technologies aim to improve the accurate detection and targeted treatment of metastatic lesions.
Improving Surgical Experience and Operational Efficiency
Beyond diagnostics, the partnership will address broader clinical workflows. The teams will work to enhance the surgical experience for patients while improving operational efficiency within healthcare settings.
Additionally, they will integrate whole-body PET/CT imaging into treatment pathways for selected cancers. They will also expand the use of anatomical and metabolic MR imaging to guide both diagnosis and therapeutic planning.
Building on a History of Innovation
As reported by Medtech Dive, this collaboration builds on Mayo Clinic’s established partnerships in imaging research. In 2023, Mayo Clinic partnered with GE HealthCare to advance radiology research. More recently, the two organisations launched an initiative to integrate imaging, AI, and patient monitoring technologies to enhance personalised cancer therapy.
Meanwhile, Siemens Healthineers and Mayo Clinic have already collaborated on initiatives to improve hospital air quality and to reduce radiation exposure from CT scanners. Therefore, the expanded agreement represents a natural progression of their longstanding innovation-driven relationship.
Driving the Future of Image-Guided, Personalised Care
Overall, the strengthened partnership underscores a shared commitment to embedding advanced imaging, AI, and minimally invasive technologies into everyday clinical practice. By combining technical innovation with clinical expertise, Siemens Healthineers and Mayo Clinic aim to redefine precision care in neurodegenerative diseases and oncology.